Asp Isotopes INC

ASP Isotopes Inc. provides a comprehensive shareholder update detailing progress in PET Labs, Renergen's helium production, and advancements in stable isotope enrichment, alongside strategic corporate developments.

ASP Isotopes Inc. announced its participation in Canaccord Genuitys 46th Annual Growth Conference on August 12, 2026, where Chief Commercial Officer Viktor Petkov will deliver a presentation.

ASP Isotopes Inc. will host a Capital Markets Day in London on September 8, 2026, to provide updates on strategic direction and commercial momentum.

ASP Isotopes Inc. announces a research agreement with Texas A&M Engineering Experiment Station to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6).

ASP Isotopes Inc. is filing a Form 8-K to retrospectively recast certain financial information from its 2025 Annual Report to present its construction services business as discontinued operations.

ASP Isotopes Inc. announced agreements to exchange approximately $109.2 million of QLE convertible notes for new shares of ASPI common stock, reducing QLE's debt by about 50% as it pursues a separate public listing.

ASP Isotopes Inc. filed its Q1 2026 Form 10-Q, detailing significant operational expansion through acquisitions and continued investment in R&D, alongside a substantial increase in operating expenses.

ASP Isotopes Inc. reported a significant net loss for Q3 2025, primarily due to non-cash fair value adjustments, while advancing strategic acquisitions and its Quantum Leap Energy spin-off plans.

ASP Isotopes Inc. reported a significantly wider net loss in Q2 2025 despite revenue growth, driven by increased operating expenses and fair value adjustments, while advancing key strategic initiatives in nuclear fuels and medical isotopes.

ASP Isotopes Inc. files its 10-Q report for the quarter ended March 31, 2025, detailing financial results and strategic advancements, including agreements with TerraPower and Renergen.

ASP Isotopes Inc. reports a net loss for the third quarter of 2024, while making progress in its isotope enrichment plant development and commercialization efforts.

ASP Isotopes Inc. reports its second quarter 2024 results, highlighting revenue growth from the PET Labs acquisition and ongoing development of isotope enrichment technologies.

ASP Isotopes Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, corporate governance, and director information.

ASP Isotopes Inc. subsidiary, Tetra 4 Proprietary Limited, has entered into a ZAR 160.7 million loan agreement with the Industrial Development Corporation of South Africa Limited to fund the acquisition of LNG dispensing plant and equipment.

ASP Isotopes Inc. files an amendment to its 2024 Annual Report on Form 10-K/A to include information previously omitted regarding directors, executive compensation, and corporate governance.

ASP Isotopes Inc. reports a net loss for 2024 while advancing commercial production of enriched isotopes and pursuing HALEU production.

ASP Isotopes has filed an amendment to its annual report to correct a typographical error regarding the effectiveness of its internal controls over financial reporting, which were deemed not effective due to previously disclosed material weaknesses.

ASP Isotopes Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

ASP Isotopes Inc. updates shareholders on strong progress in PET Labs and Renergen, with helium production set to commence and significant EBITDA targets projected.

ASPI Isotopes Inc. and ENDRA Life Sciences Inc. have announced plans for a merger, aiming to create a combined entity focused on helium and LNG production.

ASP Isotopes (Noble Africa) details proposed merger with ENDRA Life Sciences, highlighting the critical global helium shortage and the unique Virginia Gas Project.

ASP Isotopes and ENDRA Life Sciences are hosting an investor webinar to discuss the proposed merger of Noble Africa, an ASP Isotopes subsidiary focused on helium and LNG, with ENDRA.

ASP Isotopes Inc. reports that Chief Financial Officer Heather Kiessling sold shares valued at $6.28 per share as part of a pre-arranged trading plan to cover tax obligations.

Donald Ainscow, EVP, Gen Counsel, and Secretary of ASP Isotopes Inc., reported a sale of 100,000 common shares.

ASP Isotopes Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, to elect directors and ratify its independent auditor.

ASP Isotopes Inc. will hold its 2024 Annual Meeting of Stockholders virtually on November 20, 2024, to vote on director elections, an equity incentive plan, and the ratification of the company's accounting firm.

ASP Isotopes Inc.'s subsidiary, Quantum Leap Energy LLC, has acquired a controlling 79.14% voting interest in Skyline Builders Group Holding Limited to pursue critical materials supply chain opportunities.

The Vanguard Group has filed an amended Schedule 13G, indicating it no longer holds a beneficial ownership stake in ASP Isotopes Inc. following an internal realignment.

BNP Paribas Asset Management UK Ltd has disclosed a 0.9% beneficial ownership stake in ASP Isotopes Inc. as of December 31, 2025.

The Vanguard Group has reported a 5.77% beneficial ownership stake in ASP Isotopes Inc, holding 6,406,244 common shares as of December 31, 2025.

Encompass Capital Advisors LLC and Todd J. Kantor have reported a passive beneficial ownership of 5.13% in ASP Isotopes Inc.'s common stock.

AK Jensen Investment Management Ltd has reported an increased beneficial ownership of 5.4% in ASP Isotopes Inc., holding 4,955,261 common shares.

AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.3% of ASP Isotopes Inc.'s common stock.